Navigation Links
GeneGo Renews Its Agreement With Bayer Schering Pharma AG for Another Three Years
Date:1/6/2009

ST. JOSEPH, Mich., Jan. 6 /PRNewswire/ -- GeneGo, Inc., a leading provider of software and high quality manually curated databases for systems biology and pathway analysis, today announced that Bayer Schering Pharma AG has renewed its MetaCore licenses for another three years. Bayer Schering Pharma has programs for cancer, cardiovascular diseases and gynecological therapies and GeneGo has good coverage of these diseases and others. GeneGo is also in the process of building disease specific platforms in cancer and the cardiovascular area that include blueprint pathway maps for the disease, processes and mechanisms as well as offering public domain experimental data and disease ontologies.

"Bayer Schering Pharma was one of our first customers and we appreciate their loyalty," said Julie Bryant, Vice President of Business Development at GeneGo. "MetaCore is widely used in Bayer in multiple departments including bioinformatics, oncology, cardiology and women's health for data mining and analysis of multiple omics experimental data such as gene expression and proteomics."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.1(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.1(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.

For more information, please visit the company's web site at http://www.genego.com.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The Burnham Institute for Medical Research Becomes a GeneGo Center of Excellence Using MetaCore for Stem Cell Research and Neurology
2. GeneGo Is Awarded NCI Grant for Development of Systems Biology Database and Tools for Nutrition in Cancer in Collaboration with the FDA
3. MD Anderson Becomes a GeneGo Center of Excellence Using MetaCore for Oncology Research
4. University of Miami Miller School of Medicine Becomes a GeneGo Center of Excellence
5. Yale Keck Microarray Center Becomes a GeneGo Center of Excellence
6. Unilever Extends Their GeneGo MetaCore License
7. VTT Technical Research Centre of Finland Licenses MetaCore from GeneGo for Cancer Research and Diagnostics
8. GeneGo Collaborates With The Netherlands Toxicogenomics Center on $100 Million Grant
9. GSK Extends GeneGo License and Adds New Products
10. UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGos Platform
11. GeneGo Integrates With Cytoscape
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the ... the Dow Jones Industrial Average edged 0.27% lower to finish ... 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... ). Learn more about these stocks by accessing their free ...
Breaking Biology Technology:
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):